Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209-49.
DOI: 10.3322/caac.21660
Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer 2016;139(7):1534-45.
DOI: 10.1002/ijc.30211
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76(3):681-93.
DOI: 10.1016/j.jhep.2021.11.018
Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M, et al. External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 2022;12(1):28-51.
DOI: 10.1016/j.prro.2021.09.004
Park S, Jung J, Cho B, Kim SY, Yun SC, Lim YS, et al. Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35(11):1953-9.
DOI: 10.1111/jgh.15011
Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, et al. Stereotactic body radiation therapy for small (≤ 5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. Clin Mol Hepatol 2020;26(4):506-15.
DOI: 10.3350/cmh.2020.0038
Lazarev S, Hardy-Abeloos C, Factor O, Rosenzweig K, Buckstein M. Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities. J Cancer Res Clin Oncol 2018;144(10):2077-83.
DOI: 10.1007/s00432-018-2729-y
Durand-Labrunie J, Baumann AS, Ayav A, Laurent V, Boleslawski E, Cattan S, et al. Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial. Int J Radiat Oncol 2020;107(1):116-25.
DOI: 10.1016/j.ijrobp.2019.12.004
Su TS, Liang P, Lu HZ, Liang J, Gao YC, Zhou Y, et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. J Surg Oncol 2016;113(2):181-7.
DOI: 10.1002/jso.24128
Kim JY, Yoo EJ, Jang JW, Kwon JH, Kim KJ, Kay CS. Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Radiat Oncol 2013;8(1):15.
DOI: 10.1186/1748-717X-8-15
Huo YR, Eslick GD. Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared with Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol 2015;1(6):756-65.
DOI: 10.1001/jamaoncol.2015.2189
Lou J, Li Y, Liang K, Guo Y, Song C, Chen L, et al. Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis. BMC Cancer 2019;19(1):668.
DOI: 10.1186/s12885-019-5870-3
Yang JF, Lo CH, Lee MS, Lin CS, Dai YH, Shen PC, et al. Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis. Radiat Oncol Lond Engl 2019;14:180.
DOI: 10.1186/s13014-019-1382-1
Mourad M, Mabrut JY, Chellakhi M, Lesurtel M, Prevost C, Ducerf C, et al. Neoadjuvant conformal radiotherapy before liver transplantation for hepatocellular carcinoma: a propensity score matched analysis of postoperative morbidity and oncological results. Future Oncol Lond Engl 2019;15(21):2517-30.
DOI: 10.2217/fon-2019-0127
Jang WI, Bae SH, Kim MS, Han CJ, Park SC, Kim SB, et al. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy. Cancer 2020;126(2):363-72.
DOI: 10.1002/cncr.32502
Sanuki N, Kimura T, Takeda A, Ariyoshi K, Oyamada S, Yamaguchi T, et al. Final Results of a Multicenter Prospective Study of Stereotactic Body Radiation Therapy for Previously Untreated Solitary Primary Hepatocellular Carcinoma (The STRSPH Study). Int J Radiat Oncol Biol Phys 2025;121(4):942-50.
DOI: 10.1016/j.ijrobp.2024.10.040
Sun J, Zhang A, Li W, Wang Q, Li D, Zhang D, et al. Biologically effective dose (BED) escalation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma patients (≤5 cm) with CyberKnife: protocol of study. Radiat Oncol 2020;15(1):20.
DOI: 10.1186/s13014-020-1471-1
Li Z, Liu J, Zhang B, Yue J, Shi X, Cui K, et al. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nat Commun 2024;15(1):3260.
DOI: 10.1038/s41467-024-47420-3
Boldrini L, Romano A, Mariani S, Cusumano D, Catucci F, Placidi L, et al. MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach. J Cancer Res Clin Oncol 2021;147(7):2057-68.
DOI: 10.1007/s00432-020-03480-8
Xi M, Yang Z, Hu L, Fu Y, Hu D, Zhou Z, et al. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial. J Clin Oncol 2025;43(9):1073-82.
DOI: 10.1200/JCO-24-01532
Wang L, Ke Q, Huang Q, Shao L, Chen J, Wu J. Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2020;37(1):1313-21.
DOI: 10.1080/02656736.2020.1843719
Li LQ, Su TS, Wu QY, Lin ZT, Liang SX. Therapeutic Outcome of Stereotactic Body Radiotherapy for Small Hepatocellular Carcinoma Lesions-A Systematic Review and Network Meta-analysis. Clin Oncol 2023;35(10):652-64.
DOI: 10.1016/j.clon.2023.07.002
Birgin E, Hetjens S, Tam M, Correa-Gallego C, Rahbari NN. Stereotactic Body Radiation Therapy versus Surgical Resection for Stage I/II Hepatocellular Carcinoma. Cancers 2023;15(8):2330.
DOI: 10.3390/cancers15082330
Roberts SK, Majeed A, Rasaratnam K, Olynyk JK, Shackel N, Wood M, et al. National Survey of Real-World Australian Treatment Patterns for Patients with Very-Early-To Intermediate-Stage Hepatocellular Carcinoma. Cancer Med 2025;14(5):e70722.
DOI: 10.1002/cam4.70722
Sharma D, Khosla D, Meena BL, Yadav HP, Kapoor R. Exploring the Evolving Landscape of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma. J Clin Exp Hepatol 2025 [citado 22 de marzo de 2025];15(1).
DOI: 10.1016/j.jceh.2024.102386
Que JY, Lin LC, Lin KL, Lin CH, Lin YW, Yang CC. The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities. Radiat Oncol Lond Engl 2014;9:120.
DOI: 10.1186/1748-717X-9-120
Kuehnle RA, Tchelebi LT, Ludmir EB, Escorcia FE, Shrestha S, Sanford N, et al. Meta-analysis of randomized controlled trials of external-beam radiation versus transarterial chemoembolization for hepatocellular carcinoma. Cancer 2025;131(3):e35720.
DOI: 10.1002/cncr.35720
Komiyama S, Takeda A, Tateishi Y, Tsurugai Y, Eriguchi T, Horita N. Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta‐analysis. Radiother Oncol 2025;202 [citado 22 de marzo de 2025].
DOI: 10.1016/j.radonc.2024.110614
Bettinger D, Gkika E, Schultheiss M, Glaser N, Lange S, Maruschke L, et al. Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. BMC Cancer 2018;18(1):807.
DOI: 10.1186/s12885-018-4696-8
Shen PC, Chang WC, Lo CH, Yang JF, Lee MS, Dai YH, et al. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2019;105(2):307-18.
DOI: 10.1016/j.ijrobp.2019.05.066
Jia S, Lao N, Gabriel Boldt R, Mujoomdar A, Chow R, Simone CB, et al. Stereotactic body radiation therapy (Sbrt) versus transarterial chemoembolization (tace) for treatment of hepatocellular carcinoma: A meta-analysis of propensity matched studies. Univ Tor Med J 2024;101(1):12-6.
DOI: 10.33137/utmj.v101i1.41240
Bush DA, Volk M, Smith JC, Reeves ME, Sanghvi S, Slater JD, et al. Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trial. Cancer 2023;129(22):3554-63.
DOI: 10.1002/cncr.34965
Jacob R, Turley F, Redden DT, Saddekni S, Aal AKA, Keene K, et al. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non‐resectable hepatocellular carcinoma tumours of ≥ 3 cm. HPB 2015;17(2):140-9.
DOI: 10.1111/hpb.12331
Su TS, Li LQ, Meng WW, Wang YD, Chen YT, Li JX, et al. Long-Term Survival Analysis of Transarterial Chemoembolization Plus Radiotherapy vs. Radiotherapy for Hepatocellular Carcinoma with Macroscopic Vascular Invasion. Front Oncol 2020;10 [citado 30 de marzo de 2025].
DOI: 10.3389/fonc.2020.01205
Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC, et al. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma > 5 cm. BMC Cancer 2016;16(1):834.
DOI: 10.1186/s12885-016-2894-9
Buckstein M, Kim E, Özbek U, Tabrizian P, Gunasekaran G, Facciuto M, et al. Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable Single Large Hepatocellular Carcinoma: Results from a Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys 2022;114(2):221-30.
DOI: 10.1016/j.ijrobp.2022.05.021
Zhao J, Zeng L, Wu Q, Wang L, Lei J, Luo H, et al. Stereotactic Body Radiotherapy Combined with Transcatheter Arterial Chemoembolization versus Stereotactic Body Radiotherapy Alone as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review. Chemotherapy 2020;64(5-6):248-58.
DOI: 10.1159/000505739
McDevitt JL, Alian A, Kapoor B, Bennett S, Gill A, Levitin A, et al. Single-Center Comparison of Overall Survival and Toxicities in Patients with Infiltrative Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization or Drug-Eluting Embolic Transarterial Chemoembolization. J Vasc Interv Radiol 2017;28(10):1371-7.
DOI: 10.1016/j.jvir.2017.05.017
Han K, Kim JH, Yoon HM, Kim EJ, Gwon DI, Ko GY, et al. Transcatheter Arterial Chemoembolization for Infiltrative Hepatocellular Carcinoma: Clinical Safety and Efficacy and Factors Influencing Patient Survival. Korean J Radiol 2014;15(4):464-71.
DOI: 10.3348/kjr.2014.15.4.464
Oladeru OT, Miccio JA, Yang J, Xue Y, Ryu S, Stessin AM. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. J Gastrointest Oncol 2016;7(3) [citado 23 de marzo de 2025].
DOI: 10.21037/jgo.2015.10.04
Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á. Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers 2021;13(2):192.
DOI: 10.3390/cancers13020192
Hardy-Abeloos C, Lazarev S, Ru M, Kim E, Fischman A, Moshier E, et al. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization. Int J Radiat Oncol Biol Phys 2019;105(5):968-76.
DOI: 10.1016/j.ijrobp.2019.09.006
Llovet JM, Bustamante J, Castells A, Vilana R, Del Carmen Ayuso M, Sala M, et al. Natural History of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials. Hepatology 1999;29(1):62.
DOI: 10.1002/hep.510290145
Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, et al. Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. J Clin Oncol 2019;37(24):2141-51.
DOI: 10.1200/JCO.18.02184
Matsuo Y, Yoshida K, Nishimura H, Ejima Y, Miyawaki D, Uezono H, et al. Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis/inferior vena cava tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy. J Radiat Res (Tokyo) 2016;57(5):512-23.
DOI: 10.1093/jrr/rrw028
Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T, et al. Stereotactic body radiotherapy-based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol 2018;13(1):188.
DOI: 10.1186/s13014-018-1136-5
Khorprasert C, Thonglert K, Alisanant P, Amornwichet N, Thonglert K, Alisanant P, et al. Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: Feasibility and clinical outcomes. PLOS ONE 2021;16(9):e0257556.
DOI: 10.1371/journal.pone.0257556
Dutta D, Tatineni T, Yarlagadda S, Gupte A, Reddy SK, Madhavan R, et al. Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study. Indian J Gastroenterol 2021;40(4):389-401.
DOI: 10.1007/s12664-021-01172-w
Sharma D, Thaper D, Kamal R, Yadav HP. Role of stereotactic body radiotherapy for inferior vena cava tumour thrombus in hepatocellular carcinoma. J Med Imaging Radiat Oncol 2023;67(4):444-9.
DOI: 10.1111/1754-9485.13527
Dutta D, Yarlagadda S, Kalavagunta S, Nair H, Sasidharan A, Nimmya SK, et al. Co-relation of Portal Vein Tumour Thrombus Response with Survival Function Following Robotic Radiosurgery in Vascular Invasive Hepatocellular Carcinoma. J Clin Exp Hepatol 2024;14(5) [citado 12 de julio de 2025].
DOI: 10.1016/j.jceh.2024.101404
Rim CH, Kim CY, Yang DS, Yoon WS. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: A meta-analysis and systemic review. Radiother Oncol 2018;129(1):123-9.
DOI: 10.1016/j.radonc.2018.02.030
Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, et al. Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and/or Inferior Vena Cava Tumor Thrombosis. PLOS ONE 2013;8(5):e63864.
DOI: 10.1371/journal.pone.0063864
Lee SJ, Jang HS, Choi YK. Clinical outcome and toxicity of radiotherapy for inferior vena cava tumor thrombus in HCC patients: A retrospective study. Medicine (Baltimore) 2021;100(25):e26390.
DOI: 10.1097/MD.0000000000026390
Zhang D, Li Q, Li D, Jia J, Ding J, Sun J, et al. Stereotactic body radiation therapy as an effective local treatment for advanced hepatocellular carcinoma patients with inferior vena cava and right atrial tumor thrombus. BMC Gastroenterol 2022;22:451.
DOI: 10.1186/s12876-022-02556-8
Yang J, Shui Y, Liu L, Yu G, Wei Q. Insights into treatment for hepatocellular carcinoma with tumor thrombus in the inferior vena cava or right atrium. Hepatobiliary Surg Nutr 2024;13(1).
DOI: 10.21037/hbsn-23-619
Daniell KM, Banson KM, Diamond BH, Sioshansi S. Approach to Stereotactic Body Radiotherapy for the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh B-7 Cirrhosis. Curr Treat Options Oncol 2022;23(12):1761-74.
DOI: 10.1007/s11864-022-01025-4
Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, et al. Stereotactic Body Radiotherapy for Primary Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2011;81(4):e447-53.
DOI: 10.1016/j.ijrobp.2011.04.011
Lee P, Ma Y, Zacharias I, Bozorgzadeh A, Wilson S, Foley K, et al. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients with Child-Pugh B or C Cirrhosis. Adv Radiat Oncol 2020;5(5):889-96.
DOI: 10.1016/j.adro.2020.01.009
Baumann BC, Wei J, Plastaras JP, Lukens JN, Damjanov N, Hoteit M, et al. Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: High Rates of Local Control with Low Toxicity. Am J Clin Oncol 2018;41(11):1118.
DOI: 10.1097/COC.0000000000000435
Qiu H, Moravan MJ, Milano MT, Usuki KY, Katz AW. SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center. J Gastrointest Cancer 2018;49(4):463-9.
DOI: 10.1007/s12029-017-9990-1
Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014;111(3):412-7.
DOI: 10.1016/j.radonc.2014.05.002
Jackson WC, Tang M, Maurino C, Mendiratta-Lala M, Parikh ND, Matuszak MM, et al. Individualized Adaptive Radiation Therapy Allows for Safe Treatment of Hepatocellular Carcinoma in Patients with Child-Turcotte-Pugh B Liver Disease. Int J Radiat Oncol Biol Phys 2021;109(1):212-9.
DOI: 10.1016/j.ijrobp.2020.08.046
Diamond BH, Banson K, Ayash J, Lee P, Shukla UC, Jones G, et al. Outcomes After Stereotactic Body Radiation for Hepatocellular Carcinoma in Patients with Child-Pugh A Versus Child-Pugh B/C Cirrhosis. Adv Radiat Oncol 2024;9(12) [citado 19 de abril de 2025].
DOI: 10.1016/j.adro.2024.101631
Yoshino Y, Suzuki G, Shiomi H, Kimoto T, Seri S, Yamazaki H, et al. Albumin–bilirubin score is a useful predictor of worsening liver reserve after stereotactic body radiation therapy in elderly Japanese patients with hepatocellular carcinoma. J Radiat Res 2024;65(2):244-50.
DOI: 10.1093/jrr/rrae006
Kirichenko A, Uemura T, Liang Y, Hasan S, Abel S, Renz P, et al. Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma (HCC) with Single Photon Emission Computed Tomography (SPECT) Functional Treatment Planning in Patients with Advanced Hepatic Cirrhosis. Adv Radiat Oncol 2024;9(2).
DOI: 10.1016/j.adro.2023.101367
Li MF, Leung HW, Chan AL, Wang SY. Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. Ther Clin Risk Manag 2018;14:1157-68.
DOI: 10.2147/TCRM.S162898
Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, et al. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2018;100(1):122-30.
DOI: 10.1016/j.ijrobp.2017.09.001
KANG J, NIE Q, DU R, Zhang G L, Zhang G J, LI Q, et al. Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Mol Clin Oncol 2014;2(1):43-50.
DOI: 10.3892/mco.2013.196
Duan J, Zhou J, Liu C, Jiang H, Zhou J, Xie K, et al. Stereotactic body radiotherapy (SBRT) combined with transcatheter arterial chemoembolization (TACE) and tyrosine kinase inhibitors (TKIs) versus TACE and TKIs alone for unresectable hepatocellular carcinoma (uHCC) with portal vein tumor thrombus (PVTT): A randomized controlled trial. J Clin Oncol 2024;42(Suppl.16):4102-4102.
DOI: 10.1200/JCO.2024.42.16_suppl.4102
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet 2018;391(10126):1163-73.
DOI: 10.1016/S0140-6736(18)30207-1
Yu JI, Kang W, Yoo GS, Goh MJ, Sinn DH, Gwak GY, et al. Safety and Efficacy of Liver-Directed Radiotherapy in Combination with Lenvatinib for Hepatocelluar Carcinoma with Macroscopic Tumor Thrombosis. Front Oncol 2022;12 [citado 31 de marzo de 2025].
DOI: 10.3389/fonc.2022.888755
Ji X, Xu Z, Sun J, Li W, Duan X, Wang Q. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study. Radiat Oncol 2023;18(1):101.
DOI: 10.1186/s13014-023-02270-z
ji X, Zhang A, Duan X, Wang Q. Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis. Radiat Oncol 2024;19(1):143.
DOI: 10.1186/s13014-024-02527-1
O’Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012;18(8):949.
DOI: 10.1002/lt.23439
Mannina EM, Cardenes HR, Lasley FD, Goodman B, Zook J, Althouse S, et al. Role of Stereotactic Body Radiation Therapy Before Orthotopic Liver Transplantation: Retrospective Evaluation of Pathologic Response and Outcomes. Int J Radiat Oncol 2017;97(5):931-8.
DOI: 10.1016/j.ijrobp.2016.12.036
Mastrocostas K, Fischer S, Munoz-Schuffenegger P, Jang HJ, Dawson LA, Liu ZA, et al. Radiological tumor response and histopathological correlation of hepatocellular carcinoma treated with stereotactic body radiation therapy as a bridge to liver transplantation. Abdom Radiol 2021;46(4):1572-85.
DOI: 10.1007/s00261-020-02821-y
Chen B, Butler N, O’Rourke T, Hodgkinson P, Stuart K, Shih E, et al. Refining stereotactic body radiation therapy as a bridge to transplantation for hepatocellular carcinoma: An institutional experience. J Med Imaging Radiat Oncol 2023;67(3):299-307.
DOI: 10.1111/1754-9485.13509
Wang YF, Dai YH, Lin CS, Chang HC, Shen PC, Yang JF, et al. Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series. Radiat Oncol 2021;16(1):15.
DOI: 10.1186/s13014-020-01739-5
Moore A, Cohen-Naftaly M, Tobar A, Kundel Y, Benjaminov O, Braun M, et al. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiat Oncol 2017;12(1):163.
DOI: 10.1186/s13014-017-0899-4
Sandroussi C, Dawson LA, Lee M, Guindi M, Fischer S, Ghanekar A, et al. Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int 2010;23(3):299-306.
DOI: 10.1111/j.1432-2277.2009.00980.x
Garg R, Foley K, Movahedi B, Masciocchi MJ, Bledsoe JR, Ding L, et al. Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma. Adv Radiat Oncol 2021;6(1) [citado 18 de abril de 2025].
DOI: 10.1016/j.adro.2020.08.016
Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017;67(1):92-9.
DOI: 10.1016/j.jhep.2017.02.022
Wong TCL, Lee VHF, Law ALY, Pang HH, Lam KO, Lau V, et al. Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant. Hepatology 2021;74(5):2580.
DOI: 10.1002/hep.31992
Lee VHF, Vardhanabhuti V, Wong TCL, Lam KO, Choi HCW, Chiu KWH, et al. Stereotactic Body Radiotherapy and Liver Transplant for Liver Cancer: A Nonrandomized Controlled Trial. JAMA Netw Open 2024;7(6):e2415998.
DOI: 10.1001/jamanetworkopen.2024.15998
Wang S, Wang A, Lin J, Xie Y, Wu L, Huang H, et al. Brain metastases from hepatocellular carcinoma: recent advances and future avenues. Oncotarget 2017;8(15):25814-29.
DOI: 10.18632/oncotarget.15730
Zhan H, Zhao X, Lu Z, Yao Y, Zhang X. Correlation and Survival Analysis of Distant Metastasis Site and Prognosis in Patients with Hepatocellular Carcinoma. Front Oncol 2021;11 [citado 20 de abril de 2025].
DOI: 10.3389/fonc.2021.652768
Jo IY, Park HC, Kim ES, Yeo SG, Kim M, Seong J, et al. Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08). Jpn J Clin Oncol 2022;52(6):616-22.
DOI: 10.1093/jjco/hyac028
Yang A, Xiao W, Ju W, Liao Y, Chen M, Zhu X, et al. Prevalence and clinical significance of regional lymphadenectomy in patients with hepatocellular carcinoma. ANZ J Surg 2019;89(4):393-8.
DOI: 10.1111/ans.15096
Matoba M, Tsuchiya H, Kondo T, Ota K. Stereotactic body radiotherapy delivered with IMRT for oligometastatic regional lymph node metastases in hepatocellular carcinoma: a single-institutional study. J Radiat Res (Tokyo) 2020;61(5):776-83.
DOI: 10.1093/jrr/rraa067
Wang Y, Li Q, Zhang L, Liu S, Zhu J, Yang Y, et al. Efficacy and Dose-Response Relationship of Stereotactic Body Radiotherapy for Abdominal Lymph Node Metastases from Hepatocellular Carcinoma. The Oncologist 2023;28(6):e369-78.
DOI: 10.1093/oncolo/oyad083
Kim TH, Park S, Rim CH, Choi C, Seong J. Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma. J Cancer Res Clin Oncol 2021;147(9):2693-700.
DOI: 10.1007/s00432-021-03553-2
Rim CH, Park S, Yoon WS, Shin IS, Park HC. Radiotherapy for bone metastases of hepatocellular carcinoma: a hybrid systematic review with meta-analyses. Int J Radiat Biol 2023 [citado 20 de abril de 2025].
DOI: 10.1080/09553002.2022.2094020
Jung IH, Yoon SM, Kwak J, Park JH, Song SY, Lee S wook, et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma. Oncotarget 2017;8(9):15182-92.
DOI: 10.18632/oncotarget.14858
Kato H, Yoshida H, Taniguch H, Nomura R, Sato K, Suzuki I, et al. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol 2015;21(46):13101-12.
DOI: 10.3748/wjg.v21.i46.13101
Jagodinsky JC, Harari PM, Morris ZS. The Promise of Combining Radiation Therapy with Immunotherapy. Int J Radiat Oncol 2020;108(1):6-16.
DOI: 10.1016/j.ijrobp.2020.04.023
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. Cancer Res 2014;74(19):5458-68.
DOI: 10.1158/0008-5472.CAN-14-1258
Juloori A, Katipally RR, Lemons JM, Singh AK, Iyer R, Robbins JR, et al. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol 2023;115(1):202-13.
DOI: 10.1016/j.ijrobp.2022.09.052
Jiang J, Diaz DA, Nuguru SP, Mittra A, Manne A. Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. Cancers 2022;15(1):50.
DOI: 10.3390/cancers15010050
Nakabori T, Ikawa T, Kozumi K, Urabe M, Kai Y, Takada R, et al. Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy. Clin J Gastroenterol 2024;17(6):1053-7.
DOI: 10.1007/s12328-024-02030-w
100. Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol 2020;6(11):e204564.
DOI: 10.1001/jamaoncol.2020.4564
Número de descargas:
95
Número de visitas:
29
Citas:
0
